Six top tips to prepare for the new EU Clinical Trial Regulation

The European Union Clinical Trial Regulation 536/2014 (EU-CTR) aims to standardize and harmonize the conduct and management of interventional clinical trials across the European Economic Area (EEA), with legally binding rules on requirements and increased transparency. The new EU-CTR promises a simplified process designed to decrease the burden resulting from idiosyncratic interpretations of the current EU-CTD. But to reap efficiencies, sponsors must sow operational changes. This article covers the six essential preparations companies should undertake now.


Open PDF

Return to Insights Center

Related Insights

Blog

Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market

Nov 13, 2023

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Blog

Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Blog

U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?

Aug 17, 2022

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Video

Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)

Jan 26, 2022

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022

Video

On-demand webinar: An expert guide to EU-CTR

Mar 10, 2022

Blog

New Real World Evidence leader in Asia/Pacific returns to Parexel with lessons learned from China adventure

Jan 13, 2023